NeuroMetrix Inc has been issued U.S. Patent No 9,731,125 for technology that provides automated control of Quell therapy while the user sleeps, and provides feedback about one’s sleep characteristics.
Quell is a wearable device designed to help treat chronic pain that can be worn during the day and at night during sleep. It features the Quell Relief app, where users can personalize and manage their therapy discreetly. The app also measures and tracks sleep data to help users understand the amount and quality of their sleep.
“Chronic pain can be extremely disruptive to one’s quality of life. Many people find that their pain tends to increase throughout the day and peak at night. Unfortunately, those higher levels of pain can prevent them from getting to sleep and staying asleep,” said Shai N. Gozani, MD, PhD, in a media release from NeuroMetrix.
“We are therefore particularly pleased to have received this latest patent for automated regulation of Quell therapy during sleep. This patent further expands our wearable pain relief intellectual property assets and enhances our long-term competitive position.”
For more information, visit NeuroMetrix.
[Source(s): NeuroMetrix, Business Wire]
